Fig. 1.
Fig. 1. Overall survival of patients with relapsed B-cell lymphomas with 2 treatments. / Fifty-two patients were treated with 131I-tositumomab, etoposide, cyclophosphamide, and autologous stem-cell transplantation (ASCT) (thin line), and 105 patients were treated with external-beam total-body irradiation (TBI) (1.5 Gy twice a day for 4 days), etoposide (60 mg/kg), cyclophosphamide (100 mg/kg), and ASCT (thick line).

Overall survival of patients with relapsed B-cell lymphomas with 2 treatments.

Fifty-two patients were treated with 131I-tositumomab, etoposide, cyclophosphamide, and autologous stem-cell transplantation (ASCT) (thin line), and 105 patients were treated with external-beam total-body irradiation (TBI) (1.5 Gy twice a day for 4 days), etoposide (60 mg/kg), cyclophosphamide (100 mg/kg), and ASCT (thick line).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal